UBS Group
NWBO

UBS Group’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

UBS Group’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-9,012
Closed -$5K – 8511
2016
Q3 		$5K Sell
9,012
-600
-6% -$274 ﹤0.01% 7178
2016
Q2 		$6K Sell
9,612
-7,919
-45% -$8.45K ﹤0.01% 7100
2016
Q1 		$26K Sell
17,531
-217
-1% -$428 ﹤0.01% 6030
2015
Q4 		$57K Sell
17,748
-62
-0.3% -$298 ﹤0.01% 5716
2015
Q3 		$112K Buy
17,810
+4,717
+36% +$44.1K ﹤0.01% 5136
2015
Q2 		$130K Sell
13,093
-2,963
-18% -$25.9K ﹤0.01% 5208
2015
Q1 		$119K Buy
16,056
+353
+2% +$2.38K ﹤0.01% 5286
2014
Q4 		$84K Buy
+15,703
New +$80.4K ﹤0.01% 5892

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

UBS Group's NWBO Position: Q4 2016 in Review

UBS Group sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 9,012 shares — an estimated $5K sold.

UBS Group first reported a position in NWBO in Q4 2014 and held it in 8 quarters. The position peaked at $130K in Q2 2015. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • UBS Group reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • UBS Group sold 9,012 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $5K.
  • UBS Group first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2014 and held it in 8 quarters.
  • UBS Group's Northwest Biotherapeutics, Inc. Common stock position peaked at $130K in Q2 2015.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on UBS Group's 13F filing for Q4 2016, filed 14 Feb 2017.